We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11B
AUM Growth
+$1.48B
Cap. Flow
-$1.03B
Cap. Flow %
-9.36%
Top 10 Hldgs %
83.4%
Holding
140
New
7
Increased
14
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.6M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$44.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.8M
4
NGNE icon
Neurogene
NGNE
+$28.1M
5
EXEL icon
Exelixis
EXEL
+$25.4M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$24.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
3
NVAX icon
Novavax
NVAX
+$17.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
5
INSM icon
Insmed
INSM
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.07%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$2.38B 21.61%
44,100,294
+861,327
+2% +$40.8M
INCY icon
2
Incyte
INCY
$25.9B
$2.22B 20.11%
23,498,898
+201
+0% +$16.9K
ABBV icon
3
AbbVie
ABBV
$468B
$905M 8.21%
14,343,358
-30,180
-0.2% -$1.95M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$5.08B
$821M 7.45%
25,819,768
+1,303,030
+5% +$44.2M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$802M 7.28%
6,543,295
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.9B
$445M 4.04%
4,806,483
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$398M 3.61%
13,770,302
+101,436
+0.7% +$2.83M
DBVT
8
DBV Technologies
DBVT
$914M
$200M 1.82%
550,956
– –
NGNE icon
9
Neurogene
NGNE
$773M
$141M 1.28%
526,805
+139,181
+36% +$28.1M
BLCM
10
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$96.8M 0.88%
486,565
– –
CERS icon
11
Cerus
CERS
$566M
$81.1M 0.74%
13,053,275
-500,000
-4% -$3.27M
ONCE
12
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$79.2M 0.72%
1,318,341
– –
ACOR
13
DELISTED
Acorda Therapeutics
ACOR
$76.4M 0.69%
30,509
– –
AMRN
14
Amarin Corp
AMRN
$298M
$65.8M 0.6%
1,031,524
+991,431
+2,473% +$55.6M
EXEL icon
15
Exelixis
EXEL
$13.4B
$63M 0.57%
4,929,494
+2,349,494
+91% +$25.4M
ONC
16
BeOne Medicines Ltd
ONC
$42.4B
$58.9M 0.53%
1,912,680
– –
NVTA
17
DELISTED
Invitae Corporation
NVTA
$57.4M 0.52%
6,554,967
– –
HRTX icon
18
Heron Therapeutics
HRTX
$60.4M
$49.2M 0.45%
2,857,250
– –
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.44B
$48.4M 0.44%
10,963,944
-4,046,590
-27% -$16.2M
NBIX icon
20
Neurocrine Biosciences
NBIX
$15.5B
$45.3M 0.41%
895,422
– –
AAAP
21
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$39.2M 0.36%
1,029,247
+196,158
+24% +$6.53M
ARAV
22
DELISTED
Aravive, Inc. Common Stock
ARAV
$26.1M 0.24%
355,708
-98,192
-22% -$7.1M
PGNX
23
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$23.1M 0.21%
3,650,808
-319,442
-8% -$1.93M
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$22.8M 0.21%
2,466,702
+225,000
+10% +$1.88M
ARRY
25
DELISTED
Array Biopharma Inc
ARRY
$22.3M 0.2%
3,310,666
-1,000,000
-23% -$3.87M
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2016 Portfolio in Review

As of Q3 2016, Julian Baker held 140 positions worth $11B, up 16% from $9.54B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker withdrew a net $1.03B in Q3 2016, closing 6 positions and reducing 16 holdings. Its most notable exit was XENOPORT, INC., an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in ContraFect Corporation worth $10M.

  • Julian Baker's largest Q3 2016 buy was ContraFect Corporation: 5,057 shares worth $10M.
  • Julian Baker added most to Amarin Corp in Q3 2016, an estimated $55.6M increase.
  • Julian Baker's biggest Q3 2016 reduction was BioCryst Pharmaceuticals, cutting an estimated $16.2M.
  • Julian Baker fully exited XENOPORT, INC. in Q3 2016, selling an estimated $24.5M.
  • Julian Baker's ten largest holdings make up 83% of its $11B portfolio in Q3 2016.
  • Julian Baker opened 7 new positions and closed 6 in Q3 2016.
  • Julian Baker's portfolio value rose 16% quarter-over-quarter to $11B.

Based on Baker Bros. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.